Regulatoriskt pressmeddelande

Bulletin from the annual general meeting in NeoDynamics AB (publ)

The annual general meeting in NeoDynamics AB (publ) was held on 17 June 2024 at the company’s premises on Lejonvägen 14, Lidingö, whereby the shareholders primarily resolved on the following matters.

Annual report and result
The annual report and the auditor's report for the financial year 2023 were presented and the income statement and balance sheet included in the annual report were adopted.
It was resolved to not pay any dividends and that the company’s result shall be retained in the business.

Discharge from liability
The annual general meeting resolved to grant each of the members of the board of directors and the CEO discharge from liability in respect of the company for the financial year 2023.

Remuneration
It was resolved that no remuneration will be paid to the board.
It was further resolved that remuneration shall be paid to the auditor in accordance with approved invoice.

Board of directors
The annual general meeting resolved that the board shall consist of three (3) ordinary members without deputy members.
It was resolved to elect Mats Gustafsson and Erik Salén and reelect Matthew E. Colpoys, Jr., as board members for the period until the end of the next annual general meeting. Erik Salén was elected as chairman of the board.

Auditor
The annual general meeting resolved that one auditor, without deputy auditors, shall be appointed.
It was resolved to elect Ernst & Young AB (EY) as auditor, with Jakob Wojcik as principal auditor, for the period until the end of the next annual general meeting.

Authorizations
Directed issue(s)
The annual general meeting resolved to authorize the board of directors to, on one or several occasions during the period up to the next annual general meeting, increase the Company’s share capital through issues of new shares, warrants and/or convertible instruments, with or without provisions on payment by non-cash consideration and/or by way of set-off or other provisions. The board of directors shall not be able to make decisions that mean that the amount by which the share capital is increased corresponds to more than fifty (50) percent of the total share capital in the Company when the authorization is utilized for the first time.

Application on Delisting
The annual general meeting unanimously voted that NeoDynamics AB should apply for delisting.

About NeoNavia
NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

About NeoDynamics
NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2024. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.